Atrial natriuretic factor inhibits ciliary motility in cultured rabbit tracheal epithelium.
To study the effect of atrial natriuretic factor (ANF) on airway ciliary motility, we measured ciliary beat frequency by a photoelectric method in response to ANF in cultured tracheal epithelial cells from rabbits. Addition of ANF but not [Tyr8]ANF-(5-27) decreased ciliary beat frequency in a dose-dependent fashion; the maximal decrease from the baseline value was 24.1 +/- 1.5% (+/- SE, P less than 0.001), and a half-maximal inhibitory concentration (IC50) was 3 x 10(-12) M. Inhibition of neutral endopeptidase activity by phosphoramidon (10(-6) M) or thiorphan (10(-6) M) potentiated the effect of ANF so that the dose-response curve for ANF was shifted to lower concentrations by approximately 0.5 log units (P less than 0.05, in each case). The inhibition of ciliary motility induced by ANF was not affected by the blockade of arachidonic acid metabolism with indomethacin, piroxicam, or nordihydroguaiaretic acid, but it was blocked by methylene blue, a soluble guanylate cyclase inhibitor, and was potentiated by M & B 22948, a guanosine 3',5'-cyclic monophosphate (cGMP) phosphodiesterase inhibitor. The intracellular cGMP levels were increased by ANF, an effect that was further potentiated by phosphoramidon or thiorphan. These results suggest that ANF inhibits ciliary motility presumably through a guanylate cyclase-dependent regulatory pathway and that neutral endopeptidase may play a role in modulating the ANF effect on airway mucociliary transport function.
Tamaoki
J
J
First Department of Medicine, Tokyo Women's Medical College, Japan.
Kobayashi
K
K
Sakai
N
N
Kanemura
T
T
Horii
S
S
Isono
K
K
Takeuchi
S
S
Chiyotani
A
A
Yamawaki
I
I
Takizawa
T
T
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology; D002478:Cells, Cultured; D002923:Cilia / Q000187:drug effects / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D006020:Glycopeptides / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007700:Kinetics; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D008751:Methylene Blue / Q000494:pharmacology; D009068:Movement; D010894:Piroxicam / Q000494:pharmacology; D011688:Purinones / Q000494:pharmacology; D011817:Rabbits; D015244:Thiorphan / Q000494:pharmacology; D014132:Trachea / Q000502:physiology*
D004791:Enzyme Inhibitors; D006020:Glycopeptides; D007976:Leupeptins; D011688:Purinones; D010894:Piroxicam; D009637:Masoprocol; D009320:Atrial Natriuretic Factor; D002216:Captopril; D015244:Thiorphan; D007930:Leucine; C011145:zaprinast; C012211:ubenimex; C032854:leupeptin; C008890:phosphoramidon; D008751:Methylene Blue; D007213:Indomethacin